These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24321457)

  • 1. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis.
    Nishimoto T; Seta N; Anan R; Yamamoto T; Kaneko Y; Takeuchi T; Kuwana M
    Clin Exp Rheumatol; 2014; 32(2):211-7. PubMed ID: 24321457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese.
    Nishimoto K; Kochi Y; Ikari K; Yamamoto K; Suzuki A; Shimane K; Nakamura Y; Yano K; Iikuni N; Tsukahara S; Kamatani N; Okamoto H; Kaneko H; Kawaguchi Y; Hara M; Toyama Y; Horiuchi T; Tao K; Yasutomo K; Hamada D; Yasui N; Inoue H; Itakura M; Yamanaka H; Momohara S
    Ann Rheum Dis; 2010 Feb; 69(2):368-73. PubMed ID: 19336421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single nucleotide polymorphisms at the TRAF1/C5 locus are associated with rheumatoid arthritis in a Han Chinese population.
    Zhu J; Zhang D; Wu F; He F; Liu X; Wu L; Zhou B; Liu J; Lu F; Liu J; Luo R; Long W; Yang M; Ma S; Wu X; Shi Y; Wu T; Lin Y; Yang J; Yuan G; Yang Z
    BMC Med Genet; 2011 Apr; 12():53. PubMed ID: 21492465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAF1 polymorphisms associated with rheumatoid arthritis susceptibility in Asians and in Caucasians.
    Han TU; Bang SY; Kang C; Bae SC
    Arthritis Rheum; 2009 Sep; 60(9):2577-84. PubMed ID: 19714643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the TRAF1/C5 locus with increased mortality, particularly from malignancy or sepsis, in patients with rheumatoid arthritis.
    Panoulas VF; Smith JP; Nightingale P; Kitas GD
    Arthritis Rheum; 2009 Jan; 60(1):39-46. PubMed ID: 19116907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis.
    Honne K; Hallgrímsdóttir I; Wu C; Sebro R; Jewell NP; Sakurai T; Iwamoto M; Minota S; Jawaheer D
    Arthritis Res Ther; 2016 Jan; 18():12. PubMed ID: 26776603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population.
    Zervou MI; Myrthianou E; Flouri I; Plant D; Chlouverakis G; Castro-Giner F; Rapsomaniki P; Barton A; Boumpas DT; Sidiropoulos P; Goulielmos GN
    PLoS One; 2013; 8(9):e74375. PubMed ID: 24040234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between WNT1-inducible signaling pathway protein-1 (WISP-1) genetic polymorphisms and clinical aspects of rheumatoid arthritis among Chinese Han subjects.
    Kuo SJ; Hsua PW; Chien SY; Huang CC; Hu SL; Tsai CH; Su CM; Tang CH
    Medicine (Baltimore); 2019 Nov; 98(44):e17604. PubMed ID: 31689765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis.
    Daïen CI; Fabre S; Rittore C; Soler S; Daïen V; Tejedor G; Cadart D; Molinari N; Daurès JP; Jorgensen C; Touitou I
    Joint Bone Spine; 2012 Oct; 79(5):471-5. PubMed ID: 22129793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of eight polymorphisms in three candidate genes in determining the susceptibility, phenotype, and response to anti-TNF therapy in patients with rheumatoid arthritis.
    Ceccarelli F; D'Alfonso S; Perricone C; Carlomagno Y; Alessandri C; Croia C; Barizzone N; Montecucco C; Galeazzi M; Sebastiani GD; Minisola G; Fiocco U; Valesini G
    Clin Exp Rheumatol; 2012; 30(6):939-42. PubMed ID: 22992305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of TRAF1/C5 and STAT4 genes polymorphisms on susceptibility and severity of rheumatoid arthritis in Egyptian population.
    Mohamed RH; Pasha HF; El-Shahawy EE
    Cell Immunol; 2012; 273(1):67-72. PubMed ID: 22196377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy.
    Canhão H; Rodrigues AM; Santos MJ; Carmona-Fernandes D; Bettencourt BF; Cui J; Rocha FL; Canas Silva J; Polido-Pereira J; Pereira Silva JA; Costa JA; Araujo D; Silva C; Santos H; Duarte C; Cáliz R; Filipescu I; Pimentel-Santos F; Branco J; Sainz J; Plenge RM; Solomon DH; Bruges-Armas J; Da Silva JA; Fonseca JE; Karlson EW
    Biomed Res Int; 2015; 2015():490295. PubMed ID: 25834819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis.
    Kurreeman FA; Padyukov L; Marques RB; Schrodi SJ; Seddighzadeh M; Stoeken-Rijsbergen G; van der Helm-van Mil AH; Allaart CF; Verduyn W; Houwing-Duistermaat J; Alfredsson L; Begovich AB; Klareskog L; Huizinga TW; Toes RE
    PLoS Med; 2007 Sep; 4(9):e278. PubMed ID: 17880261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies.
    van Nies JA; Marques RB; Trompet S; de Jong Z; Kurreeman FA; Toes RE; Jukema JW; Huizinga TW; van der Helm-van Mil AH
    Arthritis Res Ther; 2010; 12(2):R38. PubMed ID: 20205706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
    Suarez-Gestal M; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
    Arthritis Res Ther; 2010; 12(2):R72. PubMed ID: 20423481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.
    Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z
    Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.
    Mathews RJ; Robinson JI; Battellino M; Wong C; Taylor JC; ; Eyre S; Churchman SM; Wilson AG; Isaacs JD; Hyrich K; Barton A; Plant D; Savic S; Cook GP; Sarzi-Puttini P; Emery P; Barrett JH; Morgan AW; McDermott MF
    Ann Rheum Dis; 2014 Jun; 73(6):1202-10. PubMed ID: 23687262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.